> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Harmony Biosciences' Next CEO Gets A $725,000 Salary And $2.5 Million In Stock Awards
- URL: https://www.bullished.co/harmony-biosciences-next-ceo-gets-a-725-000-salary-and-2-5-million-in-stock-awards-7ac369bd/
- Published: 2026-10-30T20:21:24.000Z
- Updated: 2026-10-30T20:21:24.000Z
- Description: An amended filing sets Peter Anastasiou's pay as CEO and a $500-an-hour consulting deal for retiring chief Jeffrey Dayno.
- Author: Matteo Parrino
- Tags: SEC Filings, HRMY, Industry: Healthcare

[Harmony Biosciences](https://www.bullished.co/tag/hrmy/), the neuroscience drug company behind the narcolepsy treatment WAKIX, has now disclosed in an [amended filing](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926120673/hrmy-20261012x8ka.htm?ref=bullished.co) that incoming CEO Peter Anastasiou will earn a [$725,000](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926120673/hrmy-20261012x8ka.htm?ref=bullished.co) base salary starting January 1, 2027\. The 8-K/A, filed Friday, also lays out the exit terms for retiring CEO Jeffrey Dayno, who will stay on as a paid consultant.

## Anastasiou's pay package

Anastasiou, now the company's Senior Executive Vice President and Chief Operating Officer, signed an amended and restated employment agreement on October 29\. It takes effect when he becomes President and CEO and joins the board as a Class I director on January 1, 2027.

His target annual bonus, starting with calendar 2027, is 75% of base salary. Within 30 days of taking over, he is eligible for an option award with a grant date fair value of $1,750,000 and restricted stock units valued at $750,000.

Each award vests 25% on the first anniversary of the January 1, 2027 start date. The remaining 75% vests quarterly until the fourth anniversary, provided he is still serving at each vesting date.

## Dayno's exit and consulting role

Dayno, who announced his retirement on October 12 as part of a succession plan, leaves as CEO and director at 11:59 p.m. Eastern Time on December 31, 2026\. Under a separation and consulting agreement also dated October 29, he receives the severance and benefits already provided in his employment and award agreements. In exchange, he gives a release of claims and agrees to keep complying with the deal and any restrictive covenants.

He is expected to advise the company through January 31, 2028\. For that work he is eligible for $500 per hour, and his existing equity awards keep vesting based on his continued service. They vest in full if a change in control occurs during the consulting period.

## What the amendment fills in

The company said it filed the amendment to add compensation and separation arrangements that had not been determined when it filed its [original 8-K](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-20261012x8k.htm?ref=bullished.co) on October 13\. Nothing else in that report changed.

Harmony sells WAKIX, a once-daily tablet for excessive daytime sleepiness and cataplexy in narcolepsy, which brought in $868.5 million in net product revenue in 2025, according to its annual report.

Anastasiou takes the CEO seat at 12:00 a.m. Eastern Time on January 1, 2027, minutes after Dayno's departure takes effect.

Learn

- [8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples →](https://www.bullished.co/learn/8-k-items-explained/)  
What every common 8-K item means, from 1.01 to 9.01: which are routine, which are rare, what to check, with real examples and counts from 90 days of filings.

### Sources

- [8-K/A Filing (Amendment) — Harmony Biosciences Holdings, Inc. (HRMY)](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926120673/hrmy-20261012x8ka.htm?ref=bullished.co) — SEC EDGAR
- [Original 8-K — Harmony Biosciences Holdings, Inc. (filed 2026-10-13)](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-20261012x8k.htm?ref=bullished.co) — SEC EDGAR

### More on Harmony Biosciences

- [Harmony Biosciences Picks COO Peter Anastasiou To Succeed CEO Jeffrey Dayno On January 1](https://www.bullished.co/harmony-biosciences-picks-coo-peter-anastasiou-to-succeed-ceo-jeffrey-dayno-on-january-1-8b9c8525/)

[All Harmony Biosciences (HRMY) coverage →](https://www.bullished.co/tag/hrmy/)